The purpose of this study is to evaluate the therapeutic efficacy of REL-1017 compared to placebo in subjects with inadequate response to ongoing antidepressant therapy.
CONTACT US ABOUT DEPRESSION TRIALMajor Depressive Disorder (Depression)
Description
Eligibility Criteria
18-65 Years Old; Diagnosed with Major Depressive Disorder; BMI between 18.0 and 32.0 kg
Duration
58 days
Intervention
On the first day of treatment, you will take 3 tablets of REL-1017 (25 mg each for a total dose of 75 mg) or placebo by mouth. On all other days, you will only take 1 tablet (25 mg) of REL-1017 or placebo.
Compensation
$100/Visit
Categories
- Adult Clinical Trial